Skip to main content
. 2024 Mar 4;6(1):88–95. doi: 10.46989/001c.94362

Table 2. Details of the course of transplantation and bradycardia.

No. Type of donor Conditioning protocols* TCI HCT-CI CSA start dosage [mg] Day of CSA treatment when bradycardia occurred Heart rate (HR) and ECG record at first episode of arrythmia CSA concentration when bradycardia occurred [ng/mL] Electrolyte levels when bradycardia occurred [mmol/l] Duration of bradycardia [days] Treatment of bradycardia
1. MUD FluBu3 RIC/RTC 2 260 2 HR = 35/min; sinus bradycardia 116 [Ca2+] = 7,8
[K+] = 4,3
[Mg2+] = 1,52
[Glc] = 80
3 CSA withdrawal, multi-electrolyte fluids infusion
2. MUD RituxFluTBI 4Gy NMA 4 300 4 HR = 42/min; sinus bradycardia 131,8 [Ca2+] = 8,7
[K+] = 4,2
[Mg2+] = 2,03
[Glc] = 89
1 CSA withdrawal
3. MUD FluBu4 MAC 3 220 2 HR = 44/min; sinus bradycardia 122 [Ca2+] = 8,5
[K+] = 4,5
[Mg2+] = 2,03
[Glc] = 86
2 CSA withdrawal, multi-electrolyte fluids infusion
4. Haploidentical BFR NMA 0 200 1 HR = 35/min; sinus bradycardia 108,3 [Ca2+] = 8,3
[K+] = 4,2
[Mg2+] = 1,71
[Glc] = 114
1 CSA withdrawal
5. MUD Cy/TBI 12 Gy MAC 0 200 2 HR = 38/min; sinus bradycardia 127 [Ca2+] = 7,9
[K+] = 4,4
[Mg2+] = 1,6
[Glc] = 96
4 CSA and beta-blocker withdrawal, multi-electrolyte fluids infusion, atropine intravenously
6. MUD FluTBI NMA 3 300 4 HR = 50/min; sinus bradycardia 156,6 [Ca2+] = 8,3
[K+] = 5,3
[Mg2+] = 1,66
[Glc] = 99
1 CSA withdrawal

Abbreviations: HSC – hematopoietic stem cells, TCI – transplant conditioning intensity, HCT-CI - Hematopoietic Cell Transplantation-specific Comorbidity Index, CSA – cyclosporine A, MUD – matched unrelated donor, SIB – sibling, FluBu3-4 – fludarabine and busulfan, RituxFluTBI – rituximab, fludarabine and total body irritation, BFR – bendamustine, fludarabine and rituximab, Cy/TBI – cyclophosphamide and total body irritation, FluTBI – fludarabine and total body irritation, RIC/RTC – reduced intensity conditioning/reduced toxicity conditioning, NMA – non-myeloablative conditioning, MAC – myeloablative conditioning

*All regimens and drug dosages were administrated according to the European Bone Marrow Transplantation (EMBT) recommendation